Collaborations & Alliances in AI and omics gain prominence
in CDx and oncology.
Beyond outright acquisitions, 2025 saw a flood of
partnerships, licensing deals, and co-development
agreements in life sciences diagnostics. These deals are
often the preferred route for accessing novel technology
or entering new markets without full acquisition.
Download the full report below.
Dx Deal Review FY 2025: Part 2
Download Request